Immunoblot analyses validated interactions of analog 19 with key BCR (BTK) and NFκB (p65, IKKβ, IKKα, RELB) pathway proteins (Fig. 3E), indicating SpiD3 affects key CLL survival pathways and disrupts both canonical and noncanonical NFκB signaling. This evidence concerns the gene IKBKB and B-cell chronic lymphocytic leukemia.